MARKET

BEAM

BEAM

Beam Therapeutics Inc.
NASDAQ
26.52
+1.79
+7.24%
After Hours: 26.34 -0.18 -0.68% 19:38 02/06 EST
OPEN
25.63
PREV CLOSE
24.73
HIGH
26.68
LOW
25.21
VOLUME
1.35M
TURNOVER
--
52 WEEK HIGH
36.44
52 WEEK LOW
13.53
MARKET CAP
2.69B
P/E (TTM)
-5.9798
1D
5D
1M
3M
1Y
5Y
1D
Beam Therapeutics announces upcoming board member resignation
TipRanks · 1d ago
Beam Therapeutics Director Carole Ho Resigns
Reuters · 1d ago
Beam Therapeutics participates in a conference call with William Blair
TipRanks · 2d ago
Analysts Are Bullish on Top Healthcare Stocks: Spectral AI (MDAI), Schrodinger (SDGR)
TipRanks · 5d ago
Cathie Wood's weekly recap: ramps up bets on JOBY, CRSP, pares ILMN, VCYT
Seeking Alpha · 5d ago
Weekly Report: what happened at BEAM last week (0126-0130)?
Weekly Report · 5d ago
Is Beam Therapeutics’ (BEAM) Alpha-1 Update Quietly Reframing the Story of Its Gene-Editing Platform?
Simply Wall St · 5d ago
Assessing Beam Therapeutics (BEAM) Valuation After Positive AATD Regulatory Update
Simply Wall St · 6d ago
More
About BEAM
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

Webull offers Beam Therapeutics Inc stock information, including NASDAQ: BEAM real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BEAM stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BEAM stock methods without spending real money on the virtual paper trading platform.